Click the icons below to search through Pioneer’s reports and documents.
|Date added||June 21, 2019|
|Category||Health Care, Life Sciences, Price Transparency, White Papers|
Date: June 21, 2019
Author: Dr. William Smith
This report examines why the Institute for Clinical and Economic Review (ICER) and the Quality Adjusted Life Years (QALY) approach to value assessment is particularly ill-suited to assess the cost-effectiveness of orphan and rare disease treatments, which represent a rapidly growing sector of the biopharmaceutical marketplace.